Step Pharma is advancing its lead CTP synthase 1 inhibitor candidate into the clinic this year in the hopes of treating an aggressive lymphoma indication with poor prognosis and limited second-line treatment options.
Step Pharma Aims To Become CTP Synthase 1 Leader, Starting With Aggressive Lymphoma
Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.
